AMRN Stock Analysis: Buy, Sell, or Hold?
AMRN - Amarin Corp Plc
$16.03
0.26 (1.65%)
▲
5d:
+7.58%
30d:
+14.09%
90d:
+6.87%
HOLD
MODERATE Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Get Alerted When AMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AMRN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AMRN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.89
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$14.84
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRN is currently trading at $16.03, which is considered extended relative to its 30-day fair value range of $14.12 to $15.18. The stock's valuation (Forward PE: 16.4) is in line with its historical norms (17.4). Remarkably, the market is currently pricing in an annual earnings decline of 2.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, AMRN is showing sideways momentum. The price is approaching resistance at $16.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AMRN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $12.50. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AMRN is showing sideways momentum. The price is approaching resistance at $16.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AMRN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $12.50. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$14.12 -
$15.18
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
47.6%
All Signals
- BEARISH: Price extended above range (+5.6% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 22.0% above Wall St target ($12.50)
Trading Range Analysis
30-Day Trading Range
$14.12 -
$15.18
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$13.81
Resistance Level
$16.31
Current Trend
Sideways
Technical data as of
Jun 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.36
Wall Street Target
$12.50
(-22.0%)
Revenue Growth (YoY)
7.4%
Earnings Growth (YoY)
-94.2%
Profit Margin
-15.5%
Valuation Discount vs History
-2.0% cheaper
PE vs Historical
16.4 vs 17.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.0%
(market-implied from PE analysis)
1-Year Target
$15.71
(-2%)
2-Year Target
$15.40
(-4%)
3-Year Target
$15.09
(-6%)
3-Yr Target (if PE normalizes)
(PE: 16→17)
$16.05
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.4 to 17.4
Stabilization Target:
$17.05
(+6.4%)
PE Expansion Potential:
+6.4%
Share & Embed Analysis
Last updated: June 21, 2026 4:14 AM ET
Data refreshes hourly during market hours. Next update: 5:14 AM
Data refreshes hourly during market hours. Next update: 5:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1216 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 58 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 57 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$221 | 58 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 53 HOLD |
